Literature DB >> 35589913

Post-alemtuzumab Graves' disease remitting after switch to ocrelizumab.

Veronica Popescu1,2, Annemie Beirinckx3, Brigitte Decallonne4,5.   

Abstract

Entities:  

Keywords:  Alemtuzumab; Autoimmunity; Graves’ disease; Multiple sclerosis; Ocrelizumab; Therapeutics

Mesh：

Substances：

Year:  2022        PMID： 35589913     DOI： 10.1007/s13760-022-01962-9

Source DB:  PubMed          Journal:  Acta Neurol Belg        ISSN： 0300-9009            Impact factor:   2.471


× No keyword cloud information.
  4 in total

1.  Alemtuzumab-induced thyroid events in multiple sclerosis: a systematic review and meta-analysis.

Authors:  L Scappaticcio; M Castellana; C Virili; G Bellastella; M Centanni; S Cannavò; A Campennì; R M Ruggeri; L Giovanella; P Trimboli
Journal:  J Endocrinol Invest       Date:  2019-08-26       Impact factor: 4.256

2.  Adjuvant rituximab, a potential treatment for the young patient with Graves' hyperthyroidism (RiGD): study protocol for a single-arm, single-stage, phase II trial.

Authors:  Michael Cole; Ann Marie Hynes; Denise Howel; Lesley Hall; Mario Abinun; Amit Allahabadia; Timothy Barrett; Kristien Boelaert; Amanda J Drake; Paul Dimitri; Jeremy Kirk; Nicola Zammitt; Simon Pearce; Tim Cheetham
Journal:  BMJ Open       Date:  2019-01-21       Impact factor: 2.692

3.  The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy.

Authors:  L Bartalena; G J Kahaly; L Baldeschi; C M Dayan; A Eckstein; C Marcocci; M Marinò; B Vaidya; W M Wiersinga
Journal:  Eur J Endocrinol       Date:  2021-08-27       Impact factor: 6.664

Review 4.  Rituximab for the treatment of multiple sclerosis: a review.

Authors:  Clara Grazia Chisari; Eleonora Sgarlata; Sebastiano Arena; Simona Toscano; Maria Luca; Francesco Patti
Journal:  J Neurol       Date:  2021-01-08       Impact factor: 6.682
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.